(0.28%) 5 114.43 points
(0.30%) 38 354 points
(0.31%) 15 977 points
(-0.93%) $83.07
(5.67%) $2.03
(0.37%) $2 355.80
(0.45%) $27.66
(3.99%) $958.90
(-0.21%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications...
Stats | |
---|---|
本日の出来高 | 3 655.00 |
平均出来高 | 15 930.00 |
時価総額 | 9.47M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-0.810 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.570 |
ATR14 | $0 (0.00%) |
Aeterna Zentaris Inc 相関
10 最も負の相関 | |
---|---|
MTRX | -0.957 |
XLRN | -0.944 |
ATRS | -0.942 |
GXII | -0.939 |
KSICU | -0.939 |
EACPU | -0.938 |
HERA | -0.938 |
MURFU | -0.937 |
HNRG | -0.936 |
ZING | -0.936 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aeterna Zentaris Inc 財務諸表
Annual | 2023 |
収益: | $4.58M |
総利益: | $4.18M (91.31 %) |
EPS: | $-3.47 |
FY | 2023 |
収益: | $4.58M |
総利益: | $4.18M (91.31 %) |
EPS: | $-3.47 |
FY | 2022 |
収益: | $5.64M |
総利益: | $5.48M (97.22 %) |
EPS: | $-7.76 |
FY | 2021 |
収益: | $5.26M |
総利益: | $5.17M (98.29 %) |
EPS: | $-1.750 |
Financial Reports:
No articles found.
Aeterna Zentaris Inc
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。